Saudi Chemical Holding Company

SASE:2230 Voorraadrapport

Marktkapitalisatie: ر.س8.4b

Saudi Chemical Holding Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Saudi Chemical Holding is de winst gegroeid met een gemiddeld jaarlijks percentage van 39.4%, terwijl de Healthcare industrie de winst jaarlijks groeide met 20.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 13.8% per jaar. Het rendement op eigen vermogen van Saudi Chemical Holding is 16%, en het heeft een nettomarge van 5.4%.

Belangrijke informatie

39.4%

Groei van de winst

39.4%

Groei van de winst per aandeel

Healthcare Groei van de industrie12.3%
Inkomstengroei13.8%
Rendement op eigen vermogen16.0%
Nettomarge5.4%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Here's Why Saudi Chemical Holding (TADAWUL:2230) Has Caught The Eye Of Investors

Oct 24
Here's Why Saudi Chemical Holding (TADAWUL:2230) Has Caught The Eye Of Investors

There's Been No Shortage Of Growth Recently For Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital

Sep 09
There's Been No Shortage Of Growth Recently For Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital

Saudi Chemical Holding Company's (TADAWUL:2230) P/E Is On The Mark

May 28
Saudi Chemical Holding Company's (TADAWUL:2230) P/E Is On The Mark

Investors Met With Slowing Returns on Capital At Saudi Chemical Holding (TADAWUL:2230)

May 07
Investors Met With Slowing Returns on Capital At Saudi Chemical Holding (TADAWUL:2230)

With EPS Growth And More, Saudi Chemical Holding (TADAWUL:2230) Makes An Interesting Case

Mar 06
With EPS Growth And More, Saudi Chemical Holding (TADAWUL:2230) Makes An Interesting Case

Saudi Chemical Holding Company's (TADAWUL:2230) 26% Jump Shows Its Popularity With Investors

Feb 10
Saudi Chemical Holding Company's (TADAWUL:2230) 26% Jump Shows Its Popularity With Investors

Saudi Chemical Holding (TADAWUL:2230) Is Reinvesting At Lower Rates Of Return

Oct 31
Saudi Chemical Holding (TADAWUL:2230) Is Reinvesting At Lower Rates Of Return

Here's Why We Think Saudi Chemical Holding (TADAWUL:2230) Might Deserve Your Attention Today

Jul 06
Here's Why We Think Saudi Chemical Holding (TADAWUL:2230) Might Deserve Your Attention Today

Saudi Chemical Holding (TADAWUL:2230) Is Due To Pay A Dividend Of SAR0.50

Jan 09
Saudi Chemical Holding (TADAWUL:2230) Is Due To Pay A Dividend Of SAR0.50

Saudi Chemical Holding (TADAWUL:2230) Has Affirmed Its Dividend Of SAR0.50

Dec 22
Saudi Chemical Holding (TADAWUL:2230) Has Affirmed Its Dividend Of SAR0.50

Here's What's Concerning About Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital

Sep 14
Here's What's Concerning About Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital

Saudi Chemical Holding (TADAWUL:2230) Will Be Hoping To Turn Its Returns On Capital Around

Dec 06
Saudi Chemical Holding (TADAWUL:2230) Will Be Hoping To Turn Its Returns On Capital Around

Does It Make Sense To Buy Saudi Chemical Holding Company (TADAWUL:2230) For Its Yield?

Apr 19
Does It Make Sense To Buy Saudi Chemical Holding Company (TADAWUL:2230) For Its Yield?

Here's What's Concerning About Saudi Chemical's (TADAWUL:2230) Returns On Capital

Mar 29
Here's What's Concerning About Saudi Chemical's (TADAWUL:2230) Returns On Capital

Is Saudi Chemical Company's (TADAWUL:2230) 2.8% ROE Worse Than Average?

Mar 01
Is Saudi Chemical Company's (TADAWUL:2230) 2.8% ROE Worse Than Average?

Does Saudi Chemical's (TADAWUL:2230) Share Price Gain of 41% Match Its Business Performance?

Feb 01
Does Saudi Chemical's (TADAWUL:2230) Share Price Gain of 41% Match Its Business Performance?

How Has Saudi Chemical (TADAWUL:2230) Allocated Its Capital?

Dec 28
How Has Saudi Chemical (TADAWUL:2230) Allocated Its Capital?

Should You Be Concerned About Saudi Chemical Company's (TADAWUL:2230) ROE?

Nov 30
Should You Be Concerned About Saudi Chemical Company's (TADAWUL:2230) ROE?

Opbrengsten en kosten

Hoe Saudi Chemical Holding geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SASE:2230 Opbrengsten, kosten en inkomsten (SAR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 246,0223263640
30 Jun 245,8692883700
31 Mar 245,4602423680
31 Dec 234,8551833560
30 Sep 234,5211173530
30 Jun 234,081933360
31 Mar 233,831803220
31 Dec 223,696803100
30 Sep 223,378512950
30 Jun 223,402482850
31 Mar 223,346612920
31 Dec 213,411702900
30 Sep 213,491532640
30 Jun 213,517642700
31 Mar 213,476772590
31 Dec 203,306742670
30 Sep 203,066463280
30 Jun 202,991413400
31 Mar 202,909323420
31 Dec 192,949333340
30 Sep 193,2261013010
30 Jun 193,1201012800
31 Mar 192,998982630
31 Dec 182,9491152450
30 Sep 182,7681282200
30 Jun 182,6501432110
31 Mar 182,5411432090
31 Dec 172,4741422110
30 Sep 172,2741291960
30 Jun 172,2061191960
31 Mar 172,2791381970
31 Dec 162,1431341940
30 Sep 162,2581682120
30 Jun 162,3031852100
31 Mar 162,3202162100
31 Dec 152,4102512070
30 Sep 152,4132661900
30 Jun 152,4522701960
31 Mar 152,4702791870
31 Dec 142,4842841860
30 Sep 142,5662921890
30 Jun 142,4503131720
31 Mar 142,3593031690
31 Dec 132,2753011630

Kwaliteitswinsten: 2230 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (5.4%) 2230 } zijn hoger dan vorig jaar (2.6%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 2230 is de afgelopen 5 jaar aanzienlijk gegroeid met 39.4% per jaar.

Versnelling van de groei: De winstgroei van 2230 over het afgelopen jaar ( 178.1% ) overtreft het 5-jarig gemiddelde ( 39.4% per jaar).

Winst versus industrie: De winstgroei 2230 over het afgelopen jaar ( 178.1% ) overtrof de Healthcare -sector 15.7%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 16% ) van 2230 wordt als laag beschouwd.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y